You can't fill a retatrutide prescription yet.
You've seen the trial results. You've also seen clinics, pharmacies and websites that say they can ship it this week. What you want is a straight answer on which of those are real.
Here is how to get retatrutide legally in the U.S. as of November 10, 2026: join a Lilly clinical trial, or have your doctor ask Lilly for expanded access. Those are the only two routes. Telehealth "prescriptions", compounded versions and vials sold online all sit outside FDA approval, and both the FDA and Lilly are acting against the companies that sell them.
🔑 Key Takeaways
- The one open trial is not a weight-loss trial. You may qualify anyway, and two tests decide it.
- Expanded access has five conditions, and you can't apply yourself. Your doctor does.
- A prescription does not make “compounded retatrutide” legal. The FDA has explained why in writing.
- Pharmacies will not have it before 2027, and one open dispute could push that later.
- You don't have to wait. Four approved medicines from the same family are available now, starting at $149 a month from the maker.
Below is each route step by step: who gets in, what it costs and how long it takes. Then what isn't legal, when pharmacies will have it, and what you can start this week instead.
How to Get Retatrutide: The Short Answer
Two routes. Both run through Lilly.
Eli Lilly makes retatrutide, and until the FDA approves it, Lilly decides who receives it. That leaves a clinical trial or a request from your doctor.
If neither row sounds like you, you are in the majority. The section on approved alternatives is where most readers end up.
Route 1: Join a Retatrutide Clinical Trial
Most of the trials are full.
We pulled every retatrutide study from ClinicalTrials.gov on November 10, 2026. Of 35 records, 22 are completed and 9 are still running but closed to new volunteers. Three are recruiting, and only one of those can put retatrutide in your hands.
The other two recruiting listings won't help you. One is an exercise study in Boston where you bring your own medicine. The other is a single-site listing in China from a sponsor that is not Lilly, and we could not confirm it.
The open trial: SYNERGY-Outcomes
It's a liver trial. That's the catch.
SYNERGY-Outcomes (NCT07165028) tests whether retatrutide or tirzepatide can prevent serious liver problems in adults with fatty liver disease, which doctors now call MASLD. Fatty liver is common in people who carry extra weight and often goes undiagnosed, so you may be closer to qualifying than you think.
At screening you need all three of these:
- Liver fat of 8% or more
- An ELF blood test score from 9 to 10.8
- Liver stiffness from 10 to under 20 kPa on a FibroScan
You are excluded if your BMI is under 25, your HbA1c is above 10%, you have type 1 diabetes or another liver disease, or you lost more than 11 pounds in the three months before screening.
The honest part: you may not get retatrutide. The study has four arms: retatrutide, tirzepatide, and a placebo group for each, and the registry does not publish the split. What softens that is the ending. When the main study finishes, eligible participants can join an optional two-year extension in which everyone receives retatrutide or tirzepatide, including people who had placebo.
How to sign up
- Ask for the two tests. If you've been told you have fatty liver, or suspect it, ask your doctor about a FibroScan and an ELF blood test. Those two results decide most of your eligibility.
- Find a site. The trial lists 141 U.S. sites in 35 states, and 137 were recruiting on November 10. Texas has 29 and Florida has 23. Search NCT07165028 on ClinicalTrials.gov or use Lilly's trial finder.
- Call. Lilly's trial line is 1-877-CTLILLY (1-877-285-4559), and the email is LillyTrials@Lilly.com. A phone call usually moves faster than a web form.
- Go to screening. Expect blood work, a liver scan and a review of your medicines.
- Start, if you are randomized in. The registry describes about 25 to 30 clinic visits over roughly 224 weeks.
Our guide to retatrutide clinical trials near me lists every U.S. site by state.
Route 2: Expanded Access Through Your Doctor
This is the closest thing to a prescription.
Lilly registered a single-patient expanded access program for retatrutide in June 2026 (NCT07629401), and its status reads "Available". Lilly's medical information page says the company "is supporting requests for expanded access to retatrutide for individual patients who meet eligibility criteria." The drug is free. The criteria are narrow.
All five must be true:
- You are 18 or older.
- Your BMI is 35 or higher even though you stayed on, and tolerated, the highest available dose of a weight-loss medicine.
- You are being treated for two or more serious or life-threatening obesity-related conditions.
- You can't join a trial of retatrutide or a similar medicine, because you don't qualify or no enrolling site is within reach.
- You and your doctor have discussed every standard option, including bariatric surgery.
The second condition stops most people. Quitting Zepbound at 5 mg because of nausea does not count; staying on the top dose and still having a BMI of 35 does.
You can't apply yourself. Your doctor calls the Lilly Answers Center at 1-800-LillyRx (1-800-545-5979). If the request meets the first screen, Lilly sends a detailed intake form. Lilly's policy says it responds in no more than five business days once it has the request and the medical information. After that, the FDA and an ethics board must sign off, and Lilly ships to your doctor, never to you.
Lilly has not said how many requests it has approved, and it describes availability as depending on geography, supply and a detailed individual assessment. Nobody can give you honest odds. A specialist obesity clinic that has filed these requests before is your best starting point.
The exact wording of each condition and the paperwork your doctor takes on are in our guide to Eli Lilly retatrutide early access.
What Is Not a Legal Way to Get Retatrutide
Three offers come up most. None is legal medicine.
A prescription does not fix this. A doctor can write one, but no U.S. pharmacy may lawfully make the product, so the prescription is paperwork on top of an unapproved drug.
The FDA puts it plainly on its page about unapproved GLP-1 drugs, last updated October 1, 2026: "Retatrutide and cagrilintide cannot be used in compounding under federal law." The same page says these drugs "have not been found safe and effective for any condition." About vials sold with lab-only labels, it says the agency "urges consumers not to purchase these products which are of unknown quality and may be harmful to their health." (FDA)
So far the FDA's letters and Lilly's lawsuits have targeted sellers, not buyers. The risk you carry is a different one: nobody has checked what is in the vial, a seller can disappear between your order and your refill, and mixing and dosing it is on you.
Plenty of people buy a vial anyway. If that is you, read our retatrutide where to buy guide first: it shows what a real batch report looks like and names the sellers the FDA and Lilly have gone after. Listed prices for retatrutide for sale online ran from $108 to $250 for a 30 mg vial when we checked on November 10, and a low price tells you nothing about what is inside.
When Will Retatrutide Be Available by Prescription?
Not before 2027, and more likely 2028.
The main phase 3 obesity trial, TRIUMPH-1, was published in the New England Journal of Medicine: 2,339 adults, 80 weeks, and an average weight loss of 25.0% on the 12 mg dose against 3.9% on placebo. Lilly funded the trial. In its July 23, 2026 release Lilly said it plans to submit retatrutide to the FDA in the first quarter of 2027, once its manufacturing data package is complete.
A standard FDA review takes about a year from submission, which points to a decision in 2028. One open dispute could push that later. Lilly and the FDA are in court over whether retatrutide should be reviewed as a drug or as a biologic. A federal appeals court heard the case on September 24, 2026, and no ruling had been posted when we checked on November 10.
Lilly has not announced a price. Our retatrutide FDA approval timeline tracks each step.
FDA-Approved Alternatives You Can Get Today
You don't have to wait for retatrutide.
If your weight is affecting your health now, four approved medicines from the same family are available in the U.S. today, and each maker publishes a self-pay price that needs no insurance. All of them need a prescription from a licensed provider.
Prices were read from the makers' own pages on November 10, 2026. The $199 Wegovy starter offer and two of the Foundayo prices are marked as ending December 31, 2026, so check the page before you plan around them.
On Medicare Part D? Since July 1, 2026 the Medicare GLP-1 Bridge covers Foundayo, Wegovy and the Zepbound KwikPen for a $50 monthly copay if you meet its criteria.
Read the chart with care. These are separate trials, so the gaps between bars are a guide and not a measurement. The first direct comparison of retatrutide and tirzepatide in obesity, TRIUMPH-5, has not reported yet.
One safety update applies to every medicine in the table. On November 9, 2026 the FDA required all approved GLP-1 medicines to add a warning about a possible increased risk of NAION, a rare condition that can cause sudden, painless vision loss in one eye (FDA). Ask your prescriber how that applies to you.
What the chart does show is that the approved options are not far behind. If you want to buy Zepbound online through LillyDirect or buy Wegovy online through NovoCare, those guides cover the steps, the telehealth options and the current prices.
What to Ask Your Doctor
Take these five questions with you.
- Could I have fatty liver disease, and should I get a FibroScan and an ELF test?
- Do I meet Lilly's five expanded access conditions, and would you file the request?
- Am I on the highest dose of my current medicine that I can tolerate?
- Which approved medicine fits my health history, and what would it cost me each month?
- I have used a vial bought online. What should we check?
Frequently Asked Questions
Sources
We pulled the trial registry, read Lilly's and the FDA's pages and copied the makers' prices on November 10, 2026. PeptideDeck is an editorial team, not a medical practice, and this page is not a substitute for your doctor.
- ClinicalTrials.gov API v2, all records listing retatrutide or LY3437943, retrieved November 10, 2026: registry search, NCT07165028 (SYNERGY-Outcomes), NCT07629401 (expanded access)
- Lilly Medical. Is there an expanded access program for retatrutide? Date of last review August 26, 2026
- Eli Lilly. Expanded access policy
- FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, content current as of October 1, 2026
- FDA letter on retatrutide in compounded drug products, March 31, 2025, sent to the National Association of Boards of Pharmacy, the Federation of State Medical Boards and the National Council of State Boards of Nursing
- Eli Lilly. Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market, August 12, 2026
- Eli Lilly. TRIUMPH-2 and TRIUMPH-3 topline results and Q1 2027 submission plan, July 23, 2026
- BioSpace. Lilly, FDA retatrutide biologic dispute comes to a head as submission nears, August 5, 2026
- U.S. Court of Appeals for the Seventh Circuit, case 26-1301, Eli Lilly and Company v. Kennedy: argued September 24, 2026; no opinion listed on November 10, 2026
- Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. 2026;395(18):1781-1793. PubMed
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PubMed
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed
- Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes Endocrinol. 2025;13(11):949-963. PubMed
- Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med. 2025;393(11):1077-1087. PubMed
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025;393(18):1796-1806. PubMed
- Medicare.gov. Weight loss drugs: Medicare GLP-1 Bridge, read November 10, 2026
- FDA Drug Safety Communication, November 9, 2026. Safety labeling changes for GLP-1 receptor agonists
- Self-pay prices read November 10, 2026: LillyDirect Zepbound, LillyDirect Foundayo, Wegovy.com
- Rubin R. Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain. JAMA. 2026;336(17):1493-1495. PubMed
